Skip to main content
OpenTrials

Clinical trial condition

Myelodysplastic-Myeloproliferative Diseases

Explore clinical trials studying Myelodysplastic-Myeloproliferative Diseases. Study availability and eligibility vary by location and protocol.

384 public trials 62 recruiting studies
Refine in advanced search Browse all conditions

Myelodysplastic-Myeloproliferative Diseases trial results

Completed

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

NCT05665530

Conditions
Acute Myeloid Leukemia (AML), Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Bone Marrow Diseases, +41 more
Locations
  • City of Hope Duarte, California, United States
  • American Oncology Partners of Maryland, PA Bethesda, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health New York, United States
View all 24 locations
View Trial Details
Completed

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

NCT01139970

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, +45 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Completed

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

NCT03268954

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +13 more
Locations
  • Southern Cancer Center - USOR Daphne, Alabama, United States
  • Southern Cancer Center - USOR Mobile, Alabama, United States
  • Southern Cancer Center - USOR Mobile, Alabama, United States
  • Southern Cancer Center- USOR Mobile, Alabama, United States
View all 242 locations
View Trial Details
Completed

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

NCT03515512

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Chronic Disease, +13 more
Locations
  • Johns Hopkins Cancer Center Baltimore, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details

Related conditions